^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma

Published date:
07/20/2020
Excerpt:
Epithelioid inflammatory myofibroblastic sarcoma (eIMS)...Xenografts were validated by confirmation of RANBP2-ALK rearrangement, perinuclear ALK localisation and CD30 expression. Although brentuximab-vedotin (BV) demonstrated single-agent activity, tumours regrew during BV therapy. BV resistance was associated with reduced CD30 expression and induction of ABCB1.
DOI:
10.1038/s41416-020-0996-2